1. Homepage
  2. Equities
  3. Netherlands
  4. Euronext Amsterdam
  5. Galapagos NV
  6. News
  7. Summary
    GLPG   BE0003818359

GALAPAGOS NV

(GLPG)
  Report
Real-time Euronext Amsterdam  -  11:35 2022-07-06 am EDT
56.20 EUR   +2.37%
06/23GALAPAGOS : to acquire CellPoint and AboundBio to accelerate access to next-generation cell therapies - Form 6-K
PU
06/23GALAPAGOS : increases share capital through subscription right exercises - Form 6-K
PU
06/22TRANSCRIPT : Abound Bio, Inc., CellPoint B.V., Galapagos NV - M&A Call
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Galapagos NV Announces Authorization of Medicines and Healthcare Products Regulatory Agency for Jyseleca, as New Treatment for Ulcerative Colitis in Great Britain

01/18/2022 | 04:01pm EDT

Galapagos NV announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a marketing authorization for Jyseleca (filgotinib 200mg tablets), as a new treatment for ulcerative colitis (UC) for Great Britain. The MHRA has licensed an additional indication for Jyseleca, an oral once-daily, JAK1 preferential inhibitor, for use in adult patients with moderately to severely active UC who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent. The submission was supported by data from the Phase 2b/3 SELECTION program, published in the Lancet. The decision from the MHRA follows authorisation from the European Commission (EC) for use in the same patient population.


© S&P Capital IQ 2022
All news about GALAPAGOS NV
06/23GALAPAGOS : to acquire CellPoint and AboundBio to accelerate access to next-generation cel..
PU
06/23GALAPAGOS : increases share capital through subscription right exercises - Form 6-K
PU
06/22TRANSCRIPT : Abound Bio, Inc., CellPoint B.V., Galapagos NV - M&A Call
CI
06/22Pharmaceutical Group Galapagos Buys Cell Therapy Developers CellPoint, AboundBio For $2..
MT
06/21Galapagos Expands Cell Therapy Capabilities Through Two Acquisitions
MT
06/21Galapagos to acquire CellPoint and AboundBio to accelerate access to next-generation ce..
GL
06/21Galapagos to acquire CellPoint and AboundBio to accelerate access to next-generation ce..
GL
06/21Galapagos NV acquired CellPoint B.V. from ND Capital and others for approximately €..
CI
06/21Galapagos NV acquired Abound Bio, Inc. for $14 million.
CI
06/20Galapagos increases share capital through subscription right exercises
GL
More news
Analyst Recommendations on GALAPAGOS NV
More recommendations
Financials
Sales 2022 543 M 553 M 553 M
Net income 2022 -129 M -131 M -131 M
Net cash 2022 3 523 M 3 586 M 3 586 M
P/E ratio 2022 -30,2x
Yield 2022 -
Capitalization 3 694 M 3 761 M 3 761 M
EV / Sales 2022 0,32x
EV / Sales 2023 0,79x
Nbr of Employees 1 305
Free-Float 74,5%
Chart GALAPAGOS NV
Duration : Period :
Galapagos NV Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GALAPAGOS NV
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 9
Last Close Price 54,90 €
Average target price 61,11 €
Spread / Average Target 11,3%
EPS Revisions
Managers and Directors
Paulus Stoffels Chairman & Chief Executive Officer
Bart Filius President, Chief Operating & Financial Officer
Walid Abi-Saab Chief Medical Officer
Howard Mitchell Rowe Independent Non-Executive Director
Katrine S. Bosley Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
GALAPAGOS NV11.54%3 697
MODERNA, INC.-38.76%61 868
IQVIA HOLDINGS INC.-23.69%40 754
LONZA GROUP AG-30.46%40 540
SEAGEN INC.14.34%32 539
CELLTRION, INC.-7.58%19 261